How Much Did PPD Raise?
Funding & Key Investors

Pharmaceutical Product Development (PPD) has solidified its market position through a series of significant capital injections, culminating in a total historical backing of $2.2B. The organization recently secured a major strategic investment of $1.6B, marking a pivotal moment in its lifecycle as it continues to scale its global contract research operations. This influx of capital underscores the firm's enduring relevance in the high-stakes landscape of drug discovery and clinical development.

What is PPD?

PPD
Business ServicesResearch & Development

Established in 1985, PPD operates as a premier contract research organization (CRO) providing comprehensive drug discovery, development, and lifecycle management services. The company serves a diverse clientele, including pharmaceutical giants, biotechnology innovators, medical device manufacturers, and government entities. By bridging the gap between laboratory research and commercial viability, PPD maintains a critical role in the global healthcare supply chain, ensuring that complex clinical trials and regulatory pathways are navigated with precision and scientific rigor.

How much funding has PPD raised?

PPD has raised a total of $2.2B across 2 funding rounds:

2017

Other Financing Round

$550M

2020

Stock Offering

$1.6B

Other Financing Round (2017): $550M with participation from GIC and Hellman & Friedman

Stock Issuance/Offering (2020): $1.6B, investors not publicly disclosed

Key Investors in PPD

GIC

A sovereign wealth fund managing Singapore's foreign reserves, GIC invests across diverse asset classes to secure long-term financial stability.

Hellman & Friedman

A San Francisco-based private equity firm specializing in buyouts and strategic investments across the healthcare, software, and professional services sectors.

Undisclosed Investor

An undisclosed institutional participant contributing to the latest financing round to support the company's ongoing strategic objectives.

What's next for PPD?

With the recent infusion of capital, PPD is well-positioned to accelerate its strategic initiatives in digital health integration and decentralized clinical trial methodologies. The firm is expected to leverage this financial momentum to enhance its technological infrastructure, thereby increasing efficiency in patient recruitment and data analytics. As the CRO sector faces increasing pressure to reduce time-to-market for life-saving therapies, PPD's focus on operational excellence and global expansion will likely remain the primary driver of its long-term growth trajectory and competitive advantage in the pharmaceutical services market.

See full PPD company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Business ServicesSoftware TestingAccounting for Legal PracticesProject Management
Business ServicesField Service Management
Business ServicesHuman Resources Management Systems (HRMS)
Business ServicesSoftware TestingProject Management

Frequently Asked Questions Regarding PPD Financial Insights

What are the most recent funding rounds that PPD has completed, and what were the funding rounds?
PPD has recently completed 2 funding rounds: Stock Offering on Feb 6, 2020, Other Financing Round on Apr 26, 2017.
What is the total amount of funding PPD has raised to date?
PPD has raised a total of $2.2B in funding to date.
How many funding rounds has PPD completed?
PPD has completed 2 funding rounds.
How much funding did PPD raise in its most recent funding round?
PPD raised $1.6B in its most recent funding round.
Which was the largest funding round in PPD's history?
The largest funding round in PPD's history was $1.6B.
See more information about PPD